MX2019010733A - Metodos para tratar la enfermedad de crohn y la colitis ulcerosa. - Google Patents

Metodos para tratar la enfermedad de crohn y la colitis ulcerosa.

Info

Publication number
MX2019010733A
MX2019010733A MX2019010733A MX2019010733A MX2019010733A MX 2019010733 A MX2019010733 A MX 2019010733A MX 2019010733 A MX2019010733 A MX 2019010733A MX 2019010733 A MX2019010733 A MX 2019010733A MX 2019010733 A MX2019010733 A MX 2019010733A
Authority
MX
Mexico
Prior art keywords
disease
methods
ulcerative colitis
crohn
jak1 inhibitor
Prior art date
Application number
MX2019010733A
Other languages
English (en)
Spanish (es)
Inventor
Y Sheikh Ahmad
M Mulhern Mathew
T Mayer Peter
Jayanth Jayanthy
D Allian Ayman
J Marroum Patrick
B Borchardt Thomas
B Thakkar Roopal
JUNGERWIRTH Steven
Paula MACHADO DE LA CERDA Ana
M Robinson Anne
Jeffrey V Enejosa Jose
L Pangan Aileen
Eslam Mohamed Mohamed-
Othman Ahmed
KLÜNDER Ben
Lars Nordstrom Fredrik
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=61750557&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2019010733(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of MX2019010733A publication Critical patent/MX2019010733A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MX2019010733A 2017-03-09 2018-03-09 Metodos para tratar la enfermedad de crohn y la colitis ulcerosa. MX2019010733A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762469337P 2017-03-09 2017-03-09
US201762470565P 2017-03-13 2017-03-13
US201762483289P 2017-04-07 2017-04-07
US201762593629P 2017-12-01 2017-12-01
PCT/US2018/021800 WO2018165581A1 (en) 2017-03-09 2018-03-09 Methods of treating crohn's disease and ulcerative colitis

Publications (1)

Publication Number Publication Date
MX2019010733A true MX2019010733A (es) 2019-11-01

Family

ID=61750557

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019010733A MX2019010733A (es) 2017-03-09 2018-03-09 Metodos para tratar la enfermedad de crohn y la colitis ulcerosa.
MX2022015499A MX2022015499A (es) 2017-03-09 2019-09-09 Metodos para tratar la enfermedad de crohn y la colitis ulcerosa.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022015499A MX2022015499A (es) 2017-03-09 2019-09-09 Metodos para tratar la enfermedad de crohn y la colitis ulcerosa.

Country Status (9)

Country Link
US (3) US20190046527A1 (enExample)
EP (2) EP3592353A1 (enExample)
JP (2) JP2020510016A (enExample)
CN (2) CN110392572A (enExample)
AU (2) AU2018230500B2 (enExample)
BR (1) BR112019018576A2 (enExample)
MX (2) MX2019010733A (enExample)
TW (2) TW202517269A (enExample)
WO (2) WO2018165581A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11780848B2 (en) 2015-10-16 2023-10-10 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1- carboxamide and solid state forms thereof
US11512092B2 (en) 2015-10-16 2022-11-29 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11524964B2 (en) 2015-10-16 2022-12-13 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US12365689B2 (en) 2015-10-16 2025-07-22 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
CN120478294A (zh) 2015-10-16 2025-08-15 艾伯维公司 制备咪唑并[1,2-a]吡咯并[2,3-e]吡嗪类化合物及其固态形式的方法
US11365198B2 (en) 2015-10-16 2022-06-21 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US10550126B2 (en) 2015-10-16 2020-02-04 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11564922B2 (en) 2017-03-09 2023-01-31 Abbvie Inc. Methods of treating crohn's disease and ulcerative colitis
CN110392572A (zh) 2017-03-09 2019-10-29 艾伯维公司 治疗克罗恩病和溃疡性结肠炎的方法
WO2020063939A1 (zh) * 2018-09-29 2020-04-02 苏州科睿思制药有限公司 一种Upadacitinib的晶型及其制备方法和用途
WO2020115212A1 (en) * 2018-12-05 2020-06-11 Lek Pharmaceuticals D.D. Crystalline phosphate salt of selective jak1 inhibitor upadacitinib
CN111909160B (zh) * 2019-05-09 2024-05-28 苏州鹏旭医药科技有限公司 一种乌帕替尼盐类化合物及其制备方法
CN110101669A (zh) * 2019-06-11 2019-08-09 南京新酶合医药科技有限公司 一种乌帕替尼颗粒的生产工艺
WO2021067465A1 (en) 2019-09-30 2021-04-08 Abbvie Inc. Treating spondyloarthritic and psoriatic conditions with upadacitinib
AU2021303629A1 (en) 2020-07-08 2023-03-09 Crystal Pharmaceutical (Suzhou) Co., Ltd. Crystal form of upadacitinib, preparation method therefor, and use thereof
US20240316040A1 (en) * 2020-12-29 2024-09-26 Abbvie Inc. Extended release upadacitinib formulations
CN114380837B (zh) * 2021-12-27 2023-06-30 上海邈金医药科技有限公司 一种具有Janus激酶抑制活性的化合物、包括该化合物的组合物及其应用
CA3246767A1 (en) * 2022-01-13 2023-07-20 Abbvie Inc. METHOD OF ADMINISTRATION OF UPADACITINIB TO AVOID DRUG INTERACTIONS AND ADVERSE EFFECTS
EP4465971A1 (en) * 2022-01-20 2024-11-27 Renata Phramaceutical (Ireland) Limited Sustained release pharmaceutical composition of upadacitinib
IL319149A (en) * 2022-09-09 2025-04-01 Intas Pharmaceuticals Ltd Upacitinib formulation
US20240242807A1 (en) * 2023-01-17 2024-07-18 Children's Hospital Medical Center Model-informed precision dosing systems for treatment of inflammatory bowel disease
WO2025149974A1 (en) * 2024-01-11 2025-07-17 Takeda Pharmaceutical Company Limited Combination therapy with an anti-alpha4beta7 antibody
CN120699157B (zh) * 2025-07-16 2025-12-16 安康市中心医院 一种治疗溃疡性结肠炎的恢复肠屏障功能抗体及其应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6448253B1 (en) 1998-09-16 2002-09-10 King Pharmaceuticals Research And Development, Inc. Adenosine A3 receptor modulators
GB0115393D0 (en) 2001-06-23 2001-08-15 Aventis Pharma Ltd Chemical compounds
GB0124299D0 (en) 2001-10-10 2001-11-28 Astrazeneca Ab Crystal structure of enzyme and uses thereof
US20030181488A1 (en) 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
US20060074102A1 (en) 2004-05-14 2006-04-06 Kevin Cusack Kinase inhibitors as therapeutic agents
CN100381175C (zh) 2004-10-09 2008-04-16 山西中医学院 一种微乳制剂及其制备方法
CN101389630A (zh) 2005-12-29 2009-03-18 艾博特公司 蛋白激酶抑制剂
CA2665214A1 (en) 2006-10-06 2008-05-29 Abbott Laboratories Novel imidazothiazoles and imidazoxazoles
AU2007352872B2 (en) 2007-05-07 2013-03-14 Evonik Operations Gmbh Solid dosage forms comprising an enteric coating with accelerated drug release
EP2170337A4 (en) 2007-06-28 2013-12-18 Abbvie Inc NEW TRIAZOLOPYRIDAZINE
WO2009118321A1 (de) 2008-03-28 2009-10-01 Boehringer Ingelheim International Gmbh Verfahren zur herstellung von säurepellets
ME02340B (me) 2008-06-10 2017-02-20 Abbvie Inc Triciklična jedinjenja
CN101904814A (zh) 2009-06-04 2010-12-08 上海恒瑞医药有限公司 制备载药乳剂的方法
EP2459180A1 (en) 2009-07-31 2012-06-06 Ranbaxy Laboratories Limited Multi-layered, multiple unit pharmaceutical compositions
ME02800B (me) 2009-12-01 2018-01-20 Abbvie Inc Nova triciklična jedinjenja
FR2991171B1 (fr) 2012-06-01 2014-05-23 Galderma Res & Dev Procede de preparation d'une composition dermatologique comprenant des oleosomes
JP6041823B2 (ja) 2013-03-16 2016-12-14 ファイザー・インク トファシチニブの経口持続放出剤形
CA2926361A1 (en) 2013-10-24 2015-04-30 Abbvie Inc. Jak1 selective inhibitor and uses thereof
US20170266289A1 (en) 2014-08-27 2017-09-21 Abbvie Inc. Topical formulation
US12133911B2 (en) 2015-06-09 2024-11-05 Capsugel Belgium Nv Formulations to achieve rapid dissolution of drug from spray-dried dispersions in capsules
CN120478294A (zh) 2015-10-16 2025-08-15 艾伯维公司 制备咪唑并[1,2-a]吡咯并[2,3-e]吡嗪类化合物及其固态形式的方法
US11365198B2 (en) 2015-10-16 2022-06-21 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US10550126B2 (en) 2015-10-16 2020-02-04 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
MX2019006821A (es) * 2016-12-14 2019-10-21 Progenity Inc Tratamiento de una enfermedad del tracto gastrointestinal con un inhibidor de cinasa de janus (jak) y dispositivos.
CN110392572A (zh) * 2017-03-09 2019-10-29 艾伯维公司 治疗克罗恩病和溃疡性结肠炎的方法

Also Published As

Publication number Publication date
US20210361647A1 (en) 2021-11-25
US20220233527A1 (en) 2022-07-28
TW202517269A (zh) 2025-05-01
AU2018230500B2 (en) 2024-03-07
CN120661512A (zh) 2025-09-19
JP2024009963A (ja) 2024-01-23
AU2024203642B2 (en) 2025-08-21
EP4487908A2 (en) 2025-01-08
WO2022178492A1 (en) 2022-08-25
MX2022015499A (es) 2023-01-24
WO2018165581A1 (en) 2018-09-13
US20190046527A1 (en) 2019-02-14
CA3052873A1 (en) 2018-09-13
TWI851536B (zh) 2024-08-11
EP4487908A3 (en) 2025-01-15
US11607411B2 (en) 2023-03-21
JP2020510016A (ja) 2020-04-02
TW201840318A (zh) 2018-11-16
AU2024203642A1 (en) 2024-06-20
AU2018230500A1 (en) 2019-09-19
BR112019018576A2 (pt) 2020-04-14
CN110392572A (zh) 2019-10-29
EP3592353A1 (en) 2020-01-15

Similar Documents

Publication Publication Date Title
MX2022015499A (es) Metodos para tratar la enfermedad de crohn y la colitis ulcerosa.
MX2023012450A (es) Esketamina para el tratamiento de la depresion.
SG10201807070YA (en) Respiratory mask with nasogastric tube path
EA201491460A1 (ru) ПРИМЕНЕНИЕ ЛАХИНИМОДА В ЛЕЧЕНИИ ПАЦИЕНТОВ С БОЛЕЗНЬЮ КРОНА, У КОТОРЫХ НЕ ЭФФЕКТИВНА ТЕРАПИЯ ПЕРВОЙ ЛИНИИ АНТИ-TNFα
SG10201902664RA (en) Combination therapy for treating cancer
NZ732507A (en) Improved compositions for treating muscular dystrophy
MX2017015896A (es) Agente anticancerigeno.
BR112015026247A2 (pt) métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor
BR112017006272A2 (pt) composição farmacêutica para tratar colite ulcerativa.
MX2016011333A (es) Sistemas de administracion de farmaco y metodo para el tratamiento de cancer de vejiga con gemcitabina.
MX377438B (es) Administracion de tasimelteon en condiciones de ayuno.
BR112016029437A2 (pt) métodos para tratamento e prevenção de doenças de instabilidade vascular
MX2023007826A (es) Metodos que comprenden una dosificacion intermitente fija de cediranib.
PH12018501790A1 (en) Treatment of patients with homozygous familial hypercholesterolemia on lipid lowering therapy
MX2016012722A (es) Metodos para tratar el virus de la hepatitis c.
EA202193276A1 (ru) Способы лечения холангиокарциномы
PH12017500617A1 (en) Dosage regimen for pegylated interferon
SG10201809673RA (en) Treatment of androgen deprivation therapy associated symptoms
MX369090B (es) Sultiame para el tratamiento de apnea del sueño.
AU2020360413A8 (en) Methods of treating conditions related to the S1P1 receptor
MX2021007324A (es) Terapia oral con acido 6,8-bis-benciltio-octanoico.
RU2009119225A (ru) Способ лечения и профилактики кокцидиозов норок
RU2014120624A (ru) Способ лечения инсульта
UA95104U (uk) Спосіб терапії хворих на негоспітальну пневмонію з супутньою хсн
Yoshida Bevacizumab/carboplatin/paclitaxel